화일약품

061250KOSDAQ의약품 제조업

47.5 / 100

Reference Date: 2026-04-13

Financial Score20.0 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 5.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Hwa-il Pharm Co., Ltd. is a company engaged in the production and sale of pharmaceutical raw materials, finished pharmaceuticals, and functional health food ingredients, with three domestic production facilities and an expansion plan for the Pyeongtaek plant. The business is accelerating growth due to the expansion of the generic drug market and increased demand for antibiotics, with sales reaching 100.8 billion KRW in 2025.

Number of Employees

145people

Average Salary

61.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

0.38Industry Average 1.047.0Point

Half of industry avg (excellent)

ROE

-0.11Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

0.13Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼9.0% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼232.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 1.8% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Neutral
화일약품, 김유정 신임 각자 대표이사 선임
화일약품은 서생규·조경숙 각자 대표이사 체제에서 서생규·김유정 각자 대표이사 체제로 전환했습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 943Won52-week high 1,37252-week low 918

1-month return2.0Point

1m -5.13% (slight drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-04-10
Neutral주권매매거래정지 (주식의 병합, 분할 등 전자등록 변경, 말소)2026-04-02
Neutral대표이사변경2026-03-30
Neutral정기주주총회결과2026-03-24
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-23